20 sources checked · Left, Center, and Right included · 45m ago
Headlines are largely factual and consistent, reporting the FDA's approval of the first m RNA flu vaccine without significant framing differences.
MOSTLY SAME
As of August 6, 2026 at 11:01 AM, this is how Optics News reads the wording differences in this story.
20 sources across Left, Center, and Right all describe the same event.
5/99 — the outlets mostly agree on the headline takeaway.
WHAT EACH SIDE EMPHASIZED
NBC News - US News · Center-left · News report
The Hill - Policy · Center · News report
American Greatness · Right · News report
SEE THE HEADLINES
The Food and Drug Administration (FDA) late Wednesday approved the nation's first m RNA flu vaccine, manufactured by drugmaker Moderna. The agency approved the shot for two separate age gro...
A younger and higher-educated base were pivotal to Abdul El Sayed’s Senate Primary win, an analysis shows.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
The FDA approved the United States’ first m RNA-based flu vaccine for adults 50 and older, drugmaker Moderna said.
Plus, what happens when you have an A.I. boss.
The vaccine, m FLUSIVA, is expected to be available for people 50 and older for the 2026-2027 respiratory illness season.
The vaccine, m FLUSIVA, is expected to be available for people 50 and older for the 2026-2027 respiratory illness season.
The vaccine, m FLUSIVA, is expected to be available for people 50 and older for the 2026-2027 respiratory illness season.
The vaccine, m FLUSIVA, is expected to be available for people 50 and older for the 2026-2027 respiratory illness season.
The vaccine, m FLUSIVA, is expected to be available for people 50 and older for the 2026-2027 respiratory illness season.
The vaccine, m FLUSIVA, is expected to be available for people 50 and older for the 2026-2027 respiratory illness season.
Good Thursday morning. Here is what’s on President Trump’s agenda today: 8:00 AM THE PRESIDENT participates in Executive Time 10:00 AM THE PRESIDENT participates in […] Source
SOURCE MAP CHANGES
Aug 6, 9:02 AM: American Greatness joined the source map.
Aug 6, 9:33 AM: KABC / ABC7 Los Angeles joined the source map.
Aug 6, 9:33 AM: WLS / ABC7 Chicago joined the source map.
Aug 6, 9:33 AM: KGO / ABC7 San Francisco joined the source map.
Now: Wording Gap is 5/99 and story health is stable · 20 sources · all three buckets · comparable news format.